Abattis receives Intl Class 5 Trademark for DefenZall in the U.S. and Taiwan

Download PDF Copy

Jan 17 2013

Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has been granted Intl Class 5 Trademark for DefenZall™ in Taiwan and the USA.

Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are pleased to extend the intellectual property of the company as we grow our brands. This mark will be used to brand our proprietary Anti-Viral Nutraceutical Platform of products which are; DefenZall Daily™, DefenZall Immune Support™ and DefenZall Serious Defense™ They will be launched through our Canadian distributor Hedley Enterprises, on the Internet and via our Distributor in Hong Kong."

Source:

Abattis Bioceuticals Corp.

Posted in: Disease/Infection News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

AI model predicts flu vaccine strains more accurately than WHO

Flu virus triggers neuropsychiatric symptoms not the medication

How shifting landscapes drive new bird flu threats across Asia

Monitoring airborne fungal spores predicts flu and COVID-19 surges

It’s almost flu season. Should you still get a shot, and will insurance cover it?

Penn State researchers reveal new function of antibody-producing cells

Local climate and wildlife factors help predict avian flu outbreaks in Europe

Does soup really work when you’re down with cold or flu?

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.